Sometime in April, FDA will hold its first ever “late-cycle” review meeting with the sponsor of a new molecular entity under the new drug review process created under the fifth version of the Prescription Drug User Fee Act.
There are a lot of things we can guess about the application: it was submitted sometime after October 1 (the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?